Recent findings published in The Lancet indicate promising progress in the treatment of sleep apnea, with a study involving 298 participants suffering from moderate to severe cases. The trial, conducted across four European nations, utilized a double-blind method where neither the participants nor the researchers were aware of who received the active medication or a placebo.
Significant Reduction in Breathing Interruptions
Participants administered higher doses of sulthiame reported a remarkable 47 percent reduction in breathing interruptions during sleep compared to those on a placebo. Additionally, these individuals exhibited enhanced oxygen levels throughout the night.
Research suggests that sulthiame may enhance the body's respiratory control and drive, thereby minimizing the risk of upper airway collapse during sleep, a primary factor in obstructive sleep apnea. The majority of side effects noted were mild and transient.
Jan Hedner, a prominent figure in pulmonary medicine at the Sahlgrenska Academy, University of Gothenburg, emphasized the significance of the findings: "Our extensive research into this treatment approach has yielded results that indicate sleep apnea can indeed be managed pharmacologically. This feels like a breakthrough, and we eagerly anticipate further studies to assess the long-term efficacy and safety for a wider range of patients," stated Hedner.
Contributions from Ludger Grote and Kaj Stenlöf, also from the University of Gothenburg, were vital to the study's success.
Challenges with Current Treatments
Obstructive sleep apnea occurs when the upper airway collapses repeatedly during sleep, leading to temporary breathing cessation, reduced oxygen levels, and significant sleep disruption. If left untreated, it can increase the risk of serious health issues, such as high blood pressure, cardiovascular problems, strokes, and type 2 diabetes.
While sleep apnea is prevalent, no medication has been designed to address its root cause directly. The most widely used treatment is continuous positive airway pressure (CPAP), which employs a mask to maintain airway openness during sleep. However, many patients struggle with CPAP usage, with up to half discontinuing it within a year due to discomfort and sleep interference.
Sulthiame, previously approved for treating a specific childhood epilepsy form, is now being explored as a potential therapeutic option for sleep apnea.